AR066450A1 - Perfil de temperatura de dos etapas para la propagacion de virus - Google Patents

Perfil de temperatura de dos etapas para la propagacion de virus

Info

Publication number
AR066450A1
AR066450A1 ARP080101903A ARP080101903A AR066450A1 AR 066450 A1 AR066450 A1 AR 066450A1 AR P080101903 A ARP080101903 A AR P080101903A AR P080101903 A ARP080101903 A AR P080101903A AR 066450 A1 AR066450 A1 AR 066450A1
Authority
AR
Argentina
Prior art keywords
stages
viruses
propagation
temperature profile
virus
Prior art date
Application number
ARP080101903A
Other languages
English (en)
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR066450A1 publication Critical patent/AR066450A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un método para la produccion de un virus. El método incluye suministrar una célula huésped ya infectada por el virus y cultivar la célula huésped infectada a dos temperaturas diferentes. Posteriormente se recolecta el virus producido mediante lasetapas de cultivo. Al utilizar el proceso de cultivo con temperatura dual se pueden obtener mayor titulacion y mejor pureza.
ARP080101903A 2007-05-04 2008-05-05 Perfil de temperatura de dos etapas para la propagacion de virus AR066450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92769307P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
AR066450A1 true AR066450A1 (es) 2009-08-19

Family

ID=39670405

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101903A AR066450A1 (es) 2007-05-04 2008-05-05 Perfil de temperatura de dos etapas para la propagacion de virus

Country Status (19)

Country Link
US (2) US8426124B2 (es)
EP (1) EP2155863B1 (es)
JP (2) JP5352578B2 (es)
KR (1) KR101581228B1 (es)
CN (2) CN101688186A (es)
AR (1) AR066450A1 (es)
AU (1) AU2008248905B2 (es)
BR (1) BRPI0811533A2 (es)
CA (1) CA2687122C (es)
CL (1) CL2008001295A1 (es)
ES (1) ES2521496T3 (es)
HK (2) HK1137780A1 (es)
IL (1) IL201896A (es)
MX (1) MX2009011899A (es)
PE (1) PE20090214A1 (es)
RU (1) RU2476594C2 (es)
TW (1) TWI447226B (es)
WO (1) WO2008135230A1 (es)
ZA (1) ZA200907744B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914163B1 (fr) * 2007-04-02 2009-06-05 Oreal Applicateur pour appliquer une composition sur les cils
US9555067B2 (en) 2012-04-18 2017-01-31 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1526172A1 (de) * 1965-04-22 1969-07-31 Steinmueller Gmbh L & C Aus mehreren Stufen aufgebauter Regenerativ-Waermeaustauscher
US4301250A (en) * 1979-11-02 1981-11-17 Merck & Co., Inc. Method of producing hepatitis B surface antigen
US4301249A (en) * 1980-07-23 1981-11-17 Merck & Co., Inc. High titer production of hepatitis A virus
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
DE19612967A1 (de) * 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
RU2181295C1 (ru) * 2000-12-27 2002-04-20 Научно-исследовательский институт вирусологии им. Д.И. Ивановского РАМН (учреждение) Вирионная цитомегаловирусная вакцина и способ ее получения
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus
WO2003085138A1 (en) * 2002-03-29 2003-10-16 Merck & Co., Inc. Methods of virus production
CN101410519B (zh) * 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
AU2005322353B2 (en) * 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses

Also Published As

Publication number Publication date
AU2008248905B2 (en) 2014-05-29
JP2010525799A (ja) 2010-07-29
ZA200907744B (en) 2010-08-25
WO2008135230A1 (en) 2008-11-13
RU2476594C2 (ru) 2013-02-27
TWI447226B (zh) 2014-08-01
CA2687122A1 (en) 2008-11-13
US20080286307A1 (en) 2008-11-20
BRPI0811533A2 (pt) 2014-10-14
US20100239606A1 (en) 2010-09-23
CN101688186A (zh) 2010-03-31
CA2687122C (en) 2017-06-13
EP2155863A1 (en) 2010-02-24
IL201896A (en) 2013-08-29
PE20090214A1 (es) 2009-03-20
HK1137780A1 (en) 2010-08-06
MX2009011899A (es) 2010-03-30
JP2013198502A (ja) 2013-10-03
JP5352578B2 (ja) 2013-11-27
CN104962525A (zh) 2015-10-07
HK1216104A1 (zh) 2016-10-14
ES2521496T3 (es) 2014-11-12
KR20100017593A (ko) 2010-02-16
IL201896A0 (en) 2011-08-01
CL2008001295A1 (es) 2009-06-26
US8426124B2 (en) 2013-04-23
TW200914616A (en) 2009-04-01
EP2155863B1 (en) 2014-08-13
JP5978172B2 (ja) 2016-08-24
KR101581228B1 (ko) 2015-12-30
RU2009144970A (ru) 2011-06-10
AU2008248905A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
UY39946A (es) Desempeño de ubicación de fad2 y su correspondiente sitio de incidencia específica de las ...*
BR112018004377A2 (pt) cepas de levedura para a expressão e secreção de proteínas heterólogas em temperaturas elevadas
CR20180094A (es) Proceso para la producción de cannabidol y delta-9-tetrahidrocannabinol
BR112012012008A2 (pt) célula, ácidos nucleicos, enzimas e seu uso bem como processo para a produção de soforolipídios.
BR112013033176A2 (pt) método para produzir uma modificação direcionada em um gene de fertilidade masculina, planta, molécula de ácido nucleio isolada, construto de expressão
EA201171018A1 (ru) Биореактор для культивирования клеток млекопитающих
BR112012026256A8 (pt) Métodos para produção de biocombustível
BR112012005844A2 (pt) Método para cultivar microalgas capazes de crescimento heterotrófico, método para fabricar um material, e sistema de biorreator
BR112013001267A2 (pt) métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
EA201491087A1 (ru) Способы получения продуктов ферментации
BR112013030830A2 (pt) processo de preparação de composto da fórmula (i) e estetrol obtido diretamente por meio do processo
WO2012014207A3 (en) Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
BR112014000837A2 (pt) aparelho para a produção de aços recozidos e processo para a produção dos ditos aços
EA201490643A1 (ru) Новые производные бетулиновой кислоты с противовирусной активностью
BR112018004861A2 (pt) processo para purificação de hidrolisado de biomassa
BR112013016863A2 (pt) processo para produzir um polistereterol
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
WO2011014416A3 (en) High yield yellow fever virus strain with increased propagation in cells
EA201300646A1 (ru) Способ получения небиволола
BR112013009163A2 (pt) processo para preparação de lubiprostona
SG194703A1 (en) Multistage cellulose hydrolysis and quench with or without acid
AR066450A1 (es) Perfil de temperatura de dos etapas para la propagacion de virus
BRPI0909695A2 (pt) processo para a preparação de nebivolol
EA201370151A1 (ru) Высокопродуктивная суспензионная клеточная линия, система и способ ее получения
BR112016016397A2 (pt) método para preparar 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carbaldeídos e 1-alquil-3-difluorometil-5-fluoro-1h-pirazol-4-carboxilatos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure